Company / Profit Margin
ALNYLAM PHARMACEUTICALS, INC. Profit Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-0.5%
FY2025
5-year range
-403.2% / -0.5%
FY2021-FY2025
Trend
+96.0%
vs FY2024
Sector context
#59 of 145
Health Care
What the data says
At -0.5%, ALNYLAM PHARMACEUTICALS, INC.'s profit margin ranks #59 of 145 in the Health Care sector. Profit Margin has increased for 5 consecutive years, from -1016.6% in FY2020 to -0.5% in FY2025.
Based on SEC 10-K filings.
-0.5% in FY2025 with a 5-year CAGR of +1016.1%.
Improved from -24.1% to -0.5% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +173.7pp
- 5-Year Change
- +1016.1pp
- 10-Year Change
- -
Sector benchmark
#59 of 145 in Health CareTop 41% of 145This company -0.5% Sector average -792.7%
▼
+99.9% above sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s profit margin has grown for 5 consecutive years.
- In FY2025, profit margin increased 96.0% year-over-year.
- Currently 792.2pp above the Health Care sector average.
- Lowest profit margin in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -0.5% | +96.0% |
| FY2024 | -12.4% | +48.6% |
| FY2023 | -24.1% | +86.2% |
| FY2022 | -174.2% | +56.8% |
| FY2021 | -403.2% | +60.3% |
| FY2020 | -1016.6% | -86.2% |
| FY2019 | -546.0% | +37.2% |
| FY2018 | -869.6% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026